Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chugai Of Japan To Make Japan-Specific Version Of Tamiflu

This article was originally published in PharmAsia News

Executive Summary

Japan's Chugai Pharmaceutical plans to produce a version of Roche's Tamiflu (oseltamivir) antiviral modified to deal with the nation's hot and humid weather. Chugai, a subsidiary of Roche, expects to deliver its specially designed version in October in a dry syrup form. The production line to be used is capable of producing enough doses per month to treat 500,000 people. Chugai plans to modify the dry syrup it gets from Switzerland so it can be stored at room temperature instead of needing to be refrigerated. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts